samedan logo
 
 
spacer
home > ict > autumn 2017 > shredding paper
PUBLICATIONS
International Clinical Trials

Shredding Paper

The informed consent process represents the keystone in a
clinical trial, the space where science meets the patient. As
healthcare began to globalise in the 1990s and 2000s, process
and presentation flexibility became crucial. With technology
spreading around the globe, the defects and difficulties in the
use of text-only documents, reported internationally for 30
years, became even more apparent. Patients worldwide decreed
that text-only paper consent forms were confusing, hard to
and sometimes in different languages. Patients frequently
breezed through paper forms without truly understanding
the material and were surprised by aspects of the trial once it
started. This led to frustration and subjects often dropped out
of the consent process or the trial itself.

With the globalisation of clinical research, creating a flexible
system that works across international boundaries, yet respects
the differences of countries and regions, is imperative.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Eric Delente, President at DrugDev Patient Solutions, has more than 20 years of experience leading technical and creative teams in the design and implementation of numerous award-winning online science, healthcare and clinical research web applications. Most recently, he led SecureConsent, the industry’s definitive eConsent solution.
spacer
Eric Delente
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioIVT Publishes New Research On the Mechanisms Underlying the C-DILI Assay

BioIVT, a leading provider of research models and services for drug development, today announced its research into the mechanisms involved in cholestatic drug-induced liver injury (DILI) has been published in Applied In Vitro Toxicology.1
More info >>

White Papers

Migration safe pharmaceutical labels improve patient safety

UPM Raflatac

Labels play an invaluable role on pharmaceutical packages. Pharmaceutical companies should only use labels that meet low-leachability and extraction requirements. Labels that are not migration safe, e.g. create leachable chemical compounds, may fail testing and result in significant launch delays or costly recalls. This white paper presents how pharmaceutical companies can ensure that the final label constructions achieve their business, regulatory and patient safety goals.
More info >>

 
Industry Events

Partnerships in Clinical Trials Europe 2018

27-29 November 2018, CCIB, Barcelona

Partnerships in Clinical Trials Europe is back – and bigger than ever. Europe’s most complete clinical meeting is bringing together 1000+ of the industry’s leading experts this November for it’s 17th annual gathering, and you’re invited!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement